Our final results reveal that tolvaptan would not substantially have an affect on HRQoL in patients with ADPKD who tolerate treatment method outside of the first three months of therapy. Your use of the translations is subject to all use constraints contained in your Electronic Products and solutions License Agreement https://ronq417wbd8.wikiparticularization.com/user